The cathepsin k inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: Results of a 4-week, double-blind, randomized, controlled trial

Clinical Breast Cancer

Volumn 10, Issue 6, 2010, Pages 452-458

  Jensen, Anders Bonde ^a   Wynne, Christopher ^b   Ramirez, Guillermo ^c   He, Weili ^d   Song, Yang ^d   Berd, Yuliya ^d   Wang, Hongwei ^d   Mehta, Anish ^d   Lombardi, Antonio ^d  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b Christchurch Clinical Studies Trust   (New Zealand)

^c Centro de Investigactiones Oncoloicas Clinica San Diego   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Bisphosphonates; Serum 1CTP; Urinary deoxypyridinoline; Zoledronic acid

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; COLLAGEN TYPE 1; CREATININE; ODANACATIB; PLACEBO; ZOLEDRONIC ACID; BIOLOGICAL MARKER; BIPHENYL DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; CATHEPSIN K; IMIDAZOLE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HORMONAL THERAPY; HUMAN; MULTICENTER STUDY; OSTEOLYSIS; PHASE 1 CLINICAL TRIAL; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; BLOOD; BONE TUMOR; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG ANTAGONISM; METASTASIS; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME; URINE;

ADULT; BIOLOGICAL MARKERS; BIPHENYL COMPOUNDS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CATHEPSIN K; COLLAGEN TYPE I; DIPHOSPHONATES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMIDAZOLES; MIDDLE AGED; TREATMENT OUTCOME;

EID: 79952278967     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.3816/CBC.2010.n.059     Document Type: Article

References (28)

1. Dhillon S, Lyseng-Williamson KA. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 2008; 68: 507-34. (Pubitemid 351342020)
2. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004; 350: 1655-64.
3. Nahleh ZA. Molecularly targeted therapy in breast cancer: the new generation. Recent Patents Anticancer Drug Discov 2008; 3: 100-4.
4. Jahanzeb M. Adjuvant trastuzumab therapy for HER2-positive breast cancer. Clin Breast Cancer 2008; 8: 324-33.
5. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc 2008; 83: 1032-45.
6. Mitrofana LM, Pelkonen J, Monkkonen J. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone 2009; 45: 1153-60.
7. Morgan C, Jeremiah S, Wagstaff J. Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. Microvasc Res 2009; 78: 453-8.
8. Rachner TD, Singh SK, Schoppet M, et al. Zoledronic acid induces apoptosis and changes the TRAIL/OPG ratio in breast cancer cells. Cancer Lett 2010; 287: 109-16.
9. Fournier P, Boissier S, Filleur S, et al. Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 2002; 62: 6538-44. (Pubitemid 35364119)
10. Hortobagyi GN, Theriault RL, Porter L, et al, Protocol 19 aredia breast cancer Study group. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91. (Pubitemid 26412396)
11. Hortobagyi GN, Theriault RL, Lipton A, et al, Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol 1998; 16: 2038-44. (Pubitemid 28265038)
12. Lipton A, Jun S. RANKL inhibition in the treatment of bone metastases. Curr Opin Support Palliat Care 2008; 2: 197-203.
13. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 2613-21. (Pubitemid 38715767)
14. Clemons MJ, Dranitsaris G, Ooi WS, et al. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 2006; 24: 4895-900. (Pubitemid 46630917)
15. Body JJ, Diel IJ, Lichinitser MR, et al. MF 4265 Study Group. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol 2003; 14: 1399-405. (Pubitemid 37185286)
16. Drake FH, Dodds RA, James IE, et al. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 1996; 271: 12511-6.
17. Troen BR. The role of cathepsin K in normal bone resorption. Drug News Perspect 2004; 70: 19-28. (Pubitemid 38419368)
18. Nomura T, Katunuma N. Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest 2005; 52: 1-9.
19. Littlewood-Evans AJ, Bilbe G, Bowler WB, et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 1997; 57: 5386-90. (Pubitemid 27516378)
20. Stoch SA, Zajic S, Stone J, et al. Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies. Clin Pharmacol Ther 2009; 86: 175-82.
21. Bone HG, McClung MR, Roux C, et al. Odanacatib, a Cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010; 25: 937-47.
22. Lipton A, Theriault RL, Hortobagyi GN, et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebocontrolled trials. Cancer 2000; 88: 1082-90. (Pubitemid 30127670)
23. Le Gall C, Bonnelye E, Clezardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr Opin Support Palliat Care 2008; 2: 218-22.
24. Lipton A, Cook R, Saad F, et al. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113: 193-201. (Pubitemid 351976401)
25. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005; 23: 4925-35. (Pubitemid 46223998)
26. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005; 97: 59-69.
27. Vinholes JJF, Purohit OP, Abbey ME, et al. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 1243-50. (Pubitemid 28164080)
28. Gauthier JY, Chauret N, Cromlish W, et al. The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K. Bioorg Med Chem Lett 2008; 18: 923-8. (Pubitemid 351179363)